We’re not sure if they celebrate Halloween in Paris but there is no way to sugarcoat the results Sanofi released this morning. When it comes to their diabetes franchise the results were downright scary; per their press release
“In the third quarter, global Diabetes sales decreased 9.2% to €1,375 million, due to lower glargine (Lantus® and Toujeo® ) sales in the U.S. Third-quarter U.S. Diabetes sales were down 24.3% to €571 million, reflecting the previously announced changes in coverage of the Part D business and a continued decline in average U.S. glargine net . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.